Table 3.

Phage and phage lysin therapy in human clinical trials published between January 2007 and March 2019.

Trial Start	Trial Registration Number	Ref.	Phage/Lysin Formulation (Investigator/Sponsor)	Bacteria Targeted	Treatment Indication	Phase	Outcome
2006		[21]	WPP-201 cocktail (Southwest Regional Wound Care Center)	Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus	Infected venous leg ulcers	I	No adverse effects observed
2009		[61]	T4 coliphage cocktail: AB2, 4, 6, 11, 46, 50, 55, JS34, 37, 98, D1.4 (Nestlé)	E. coli	Dysentery	I/II	No adverse effects or benefits noted; study prematurely discontinued
2009	EudraCT 2004–001691–39	[247]	Biophage-PA (Biocontrol Ltd)	P. aeruginosa	Otitis externa	I/II	No adverse effects noted; at 42 days post-treatment, phage-treated cohort exhibited reduced median bacterial abundance compared to placebo group
2015		[21]	PhagoBurn (Pherecydes Pharma)	P. aeruginosa, E. coli	Infected burn wounds	I/II	No adverse effects noted; time to “sustained bacterial reduction” longer in phage treatment arm; study prematurely discontinued
2017		N/A	SAL200 (Tonabacase) (iNtRON Biotech)	S. aureus	S. aureus bacteremia	II	Ongoing
2017		[137]	Exebacase (ContraFect Corp)	S. aureus	Bacteremia, including endocarditis (single intravenous dose added to standard of care antibiotics)	II	Well tolerated; higher clinical response rate compared to standard of care antibiotics alone in methicillin-resistant but not methicillin-susceptible S. aureus subgroups
2017		N/A	Pyophage (Tzulakidze National Center of Urology)	Enterococcus species, E. coli, Proteus mirabilis, staphylococci, streptococci, P. aeruginosa	Urinary tract infections	II/III	Results pending (personal communication, Thomas Kessler)
2019		N/A	EcoActive (Intralytix, Inc.)	Adherent invasive E. coli (AIEC)	Exacerbation of inflammation in Crohn disease secondary to AIEC	I/II	Recruitment ongoing
2019		N/A	PhagoPied (Pherecydes Pharma)	S. aureus	Diabetic wounds	I/II	Not yet recruiting

Table reproduced from [174]